Navigation Links
Juvéderm Voluma Declared Effective by the FDA
Date:5/16/2013

Los Angeles, CA (PRWEB) May 16, 2013

According to an April 30, 2013 CNBC article, titled “FDA Staff Says Allergan's New Dermal Filler Effective” (Go to goo.gl/kQJKk), the US Food and Drug Administration (FDA) recently declared that Juvéderm Voluma XC, a dermal filler product manufactured by Allergan Inc., is effective in correcting volume deficits in the middle of the face. The FDA reported that after six months of Juvéderm Voluma XC treatments, there is a significant improvement in the appearance of facial wrinkles and folds in the center of the face.

“I look forward to being able to offer Juvéderm Voluma XC to my patient,” says Dr. Simon Ourian, Medical Director of Epione Beverly Hills. “Everything I’ve heard and read until now indicates that it works well to restore lost facial volume.”

The article noted that the FDA reviewers who conducted the preliminary review of Juvéderm Voluma XC indicated that if the FDA advisory panel approved the dermal filler, Allergan should be compelled to perform further safety tests. Before the approval was announced, some analysts had predicted that based on Allergan Inc.’s track record and the quality of the other products manufactured by the company, there was a high likelihood of the FDA clearing Juvéderm Voluma XC.

Although two of the FDA reviewers initially dissented from the opinion, on May 2, 2013 the independent advisory panel of the Federal Drug Administration voted on the safety, effectiveness and risk benefit profile of this dermal filler, and unanimously declared that is an effective injectable that has the ability to correct age related problems such as folds and wrinkles in the mid-face.

“It is important to note that prior to the FDA's declaration that Juvéderm Voluma XC is effective, it had previously approved an earlier version of Juvéderm in 2006,” says Dr. Ourian, “and I’ve been using it in my practice since that time. I found it to be an effective product and I expect Juvéderm Voluma to be a benefit to my patients too.”

Dr. Ourian has been a pioneer in laser technology and non-invasive aesthetic procedures including Restylane, Juvéderm, Radiesse and Sculptra. These treatments are used for the correction or reversal of a variety of conditions such as acne, acne scars, skin discoloration, wrinkles, stretch marks, varicose veins, cellulite, and others. More information about the pending approval of Juvéderm Voluma XC can be found on Epione’s website.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10738326.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Days for Girls International Declared a Nike Girl Effect Champion
2. Pelvic organ prolapse surgery less effective than expected
3. Procedure for Incontinence in Women May Lose Effectiveness With Time
4. New Global Study Pinpoints Main Causes of Childhood Diarrheal Diseases, Suggests Effective Solutions
5. Weight Loss Solutions
6. How “Customized Fat Loss” Helps People Lose Fat Effectively – V kool
7. Dermatologists in San Diego Say Botox is a Safe & Effective Treatment for Migraine & Tension Headache Relief
8. Silk and cellulose biologically effective for use in stem cell cartilage repair
9. Exercise proves to be ineffective against care home depression
10. Weight loss surgery safe and effective for an expanded group of patients
11. Mariner Biomedical Announces Results From an Independent Laboratory Confirming Deter Insect Repellent™ Effectively Repels Mosquitoes for 6 Hours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board of ... Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve ... Puffer’s retirement at the end of 2018. Upon assuming the role of President and ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology: